India, along with South Africa, played a pivotal role in advocating for a temporary waiver of certain provisions of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) at the World Trade Organization (WTO) for COVID-19 vaccines, therapeutics, and diagnostics. This proposal, first put forth in October 2020, aimed to address the global inequities in access to life-saving medical tools during the pandemic.

India's Position and Rationale:

1. COVID-19 Products as Global Public Goods: India's core argument was that during an unprecedented global health crisis, COVID-19 vaccines, treatments, and diagnostics should be treated as 'global public goods.' This implies that access to these essential tools should not be restricted by intellectual property (IP) barriers, which prioritize commercial interests over public health.

2. Ensuring Equitable and Affordable Access: The primary objective of the waiver was to ensure equitable, timely, and affordable access to COVID-19 medical products, especially for developing and least developed countries. These nations faced immense challenges in procuring sufficient doses due to limited production capacity, high prices, and supply hoarding by wealthier nations.

3. Addressing Vaccine Inequity: India highlighted the stark disparity in vaccine distribution globally, where developed countries had secured multiple times their population's needs, while many developing nations struggled to vaccinate even their frontline workers. India argued that IP barriers were a major impediment to scaling up global production and distribution, thereby exacerbating this inequity.

4. Facilitating Diversified Production: A temporary waiver would allow countries with manufacturing capabilities (like India, a major vaccine producer) to produce generic versions of patented vaccines and treatments without fear of legal repercussions for patent infringement. This would significantly increase the global supply, reduce prices, and lessen reliance on a few pharmaceutical companies, thereby enhancing global resilience to future pandemics.

5. Public Health Over Private Profit: India consistently emphasized that in a global health emergency, the imperative of saving lives and protecting public health must take precedence over the commercial interests of pharmaceutical companies and the protection of their intellectual property rights.

6. Temporary and Targeted Measure: The proposal was for a temporary waiver, specifically for the duration of the pandemic, and was targeted only at COVID-19 related medical products, not a blanket or permanent change to the TRIPS agreement.

Challenges and Outcome:

The proposal faced strong opposition from several developed countries (including the EU, UK, Switzerland, and initially the US) and pharmaceutical industry groups, who argued that IP protection incentivizes innovation and that a waiver would not solve complex manufacturing challenges or supply chain issues. However, the US, under the Biden administration, eventually shifted its stance to support a waiver for vaccines (though not for therapeutics or diagnostics), providing significant momentum.

After prolonged and complex negotiations, WTO members reached a compromise decision in June 2022. This decision allowed eligible developing countries to authorize the use of patented COVID-19 vaccines without the consent of the patent holder, under certain conditions. While it was a narrower waiver than initially proposed by India and South Africa, with limitations on scope and eligibility, India welcomed it as a step towards addressing vaccine inequity, while continuing to advocate for a broader waiver covering therapeutics and diagnostics.

In essence, India's position was a principled stand for global health equity, advocating for a temporary suspension of IP rights to ensure that life-saving medical innovations are accessible to all during a global crisis.